Objective-To perform a systematic review and meta-analysis to examine whether rheumatic disease is associated with an increased carotid intima-media thickness (CIMT; increasingly used as a surrogate marker for atherosclerosis) when compared with healthy control subjects. Methods and Results-A prespecified search strategy was used to identify relevant studies in the MEDLINE and EMBASE databases (January 1, 1986 to December 31, 2008. Methodological quality was assessed using the Newcastle-Ottawa score for observational studies. A total of 68 controlled comparisons from 60 different studies were reviewed: 25 (37%) on rheumatoid arthritis, 24 (35%) on systemic lupus erythematosus, 6 (9%) on systemic sclerosis, and 13 (19%) on other rheumatic diseases. Random-effects meta-regression analysis was performed. The estimated summary effect size between control and study subject CIMT measurement comparisons, with preexisting cardiovascular disease excluded, was 0.64 (95% CI, 0.46 to 0.82). This represented an overall absolute mean difference of 0.06 mm (95% CI, 0.05 to 0.06 mm). Preexisting cardiovascular disease, rheumatic disease type, and disease duration contributed to heterogeneity. Conclusion-Accelerated atherosclerosis is a common complication of autoimmune rheumatic diseases, with early changes seen even in pediatric patients. CIMT was significantly increased in rheumatic disease populations. Future studies need to use a standardized protocol to ensure clinically meaningful results when measuring CIMT as a surrogate for premature atherosclerosis. (Arterioscler Thromb Vasc Biol. 2010;30:1014-1026.) 
B eginning in the early 1970s, accelerated atherosclerosis leading to premature cardiovascular disease (CVD) began to be recognized as a significant cause of morbidity and mortality in autoimmune diseases and in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) in particular. [1] [2] [3] This was initially believed to be due to traditional risk factors for atherosclerosis and the use of certain drugs, specifically corticosteroids. However, more recently, it has been shown that traditional risk factors alone cannot explain the extent of observed premature atherosclerosis and that the chronic inflammation seen in patients with autoimmune diseases is an important contributing factor. 4 It has also been demonstrated that the atherosclerotic process starts in childhood 5, 6 and that chronic inflammation, as demonstrated by an elevated C-reactive protein level, leads to early CVD. 7 The results of a recent systematic review 8 showed that RA is associated with a 60% increase in the risk of CVD-related death. Furthermore, a recent comparative study 9 between RA and diabetes mellitus suggested that preclinical atherosclerosis appears to be of equal frequency and severity, and that CVD risk factors in those with RA may need to be targeted as aggressively as in patients with diabetes. The identification of subclinical atherosclerosis before cardiovascular or cerebrovascular events is needed to allow the clinician to design preventive therapy.
See accompanying article on page 892
Noninvasive surrogate markers of early atherosclerosis have been developed to allow the early detection of atherosclerosis before overt disease. High-resolution ultrasonographic measurement of the carotid intima-media thickness (CIMT) is one such method. Multiple studies have shown that changes in CIMT can be used as a surrogate end point for determining the success of interventions to decrease the risk of CVD. A recent systematic review and meta-analysis 10 has shown that CIMT can be used as a predictor of future vascular events in otherwise healthy individuals. In particular, it was shown that for an absolute CIMT difference of 0.1 mm, the future risk of myocardial infarction increases by 10% to 15%, and the stroke risk increases by 13% to 18%.
The aims of this systematic review and meta-analysis were as follows: (1) to examine whether rheumatic diseases are associated with an increased CIMT when compared with healthy control subjects and (2) to provide summary estimates for the effect size for all populations together and then stratified by preexisting CVD and rheumatic disease type.
Methods

Search Strategy
A prespecified search strategy was used to identify when CIMT first appeared in the literature, including relevant studies in the MEDLINE (January 1, 1986 to December 31, 2008) and EMBASE (January 1986 to December 2008) databases. The keywords for the searches were as follows: carotid intima-media thickness; flowmediated dilatation and pulse wave velocity and myocardial infarction; stroke; cardiovascular disease; carotid artery disease; and death and rheumatic disease. Variants for all keywords were used to increase the number of studies returned by the search. Flowmediated dilatation and pulse wave velocity were included as keywords in the search because these 2 modalities are often used along with CIMT in study protocols; this helped to minimize the chances of missing a relevant article. The references in the identified or related articles were then manually reviewed in the search for other relevant citations. All resulting articles were then screened for CIMT measures and the inclusion of healthy control groups.
Inclusion Criteria
The inclusion criteria were as follows: (1) cohort or cross-sectional studies with data on both patients diagnosed as having a rheumatic disease and healthy age-and sex-matched controls and (2) use of high-resolution ultrasonography to measure CIMT. All subjects diagnosed as having rheumatic diseases needed to fulfill the standard accepted diagnostic criteria, and healthy controls needed to be clearly described to be included in our analysis. Final inclusion of the studies was determined by both reviewers independently (P.N.T. and T.J.B.). If a study was reported in more than 1 publication, we considered all publications for data abstraction; however, only 1 report was included in our study. If a given publication included several groups of patients, the study yielded a corresponding number of comparisons in our database. The 6 publications that were not available in English were assessed, and data were extracted with the help of a translator. In 5 publications that did not contain all the information necessary for meta-analysis and/or quality assessment, missing information was requested directly from the authors.
Data Extraction
The quality of the studies was assessed and scored by 2 of us (P.N.T. and T.J.B.) using the Newcastle-Ottawa quality assessment scale (NOS) for observational studies. From each study, the following data items were extracted: study design, recruitment and number of patients, rheumatic disease studied, disease duration, inclusion or exclusion of patients with preexisting CVD, sex and age distribution, mean and SD CIMT, and ultrasonographic method, including type (B or M mode), location of measurements (common carotid artery [CCA], bifurcation carotid artery, or internal carotid artery; right or left side; and near or far wall), inclusion or exclusion of plaque in CIMT measurement, interrater and/or intrarater variation, and blinding. In case of uncertainty, issues were resolved by consensus with 1 of us (E.D.S.).
Statistical Analysis
The effect size for each study was calculated using the standardized mean difference, Cohen's D 11 Ϫ1)*SD[c] 2 )/(N)) with eϭexposed and cϭcontrol. These estimates and 95% CIs were illustrated with a Forest plot and graphed by disease type. Pooled estimates were calculated using a fixed-effects model (to test and assess the level of heterogeneity) and a random-effects model 12 to obtain an average effect size and to study heterogeneity. Heterogeneity was tested with the 2 heterogeneity statistic Q and quantified using I 2 , which is a measure that describes the percentage of total variation across comparisons that is the result of heterogeneity rather than chance. 13 We considered I 2 values of 25%, 50%, and 75% to indicate low, moderate, and high variation, respectively. 14 Metaregression was performed modeling the following independent variables: age, sex (female to male ratio), disease duration, NOS score, disease type (RA, SLE, systemic sclerosis [SSc], and other rheumatic disease), exclusion or nonexclusion of plaque in the CIMT measurement, and exclusion or nonexclusion of subjects diagnosed as having preexisting CVD. This last parameter was tested in a multivariable model adjusting for age, sex ratio, and disease duration. Continuous variables were centered to their respective group mean before being entered into meta-regression analysis. Heterogeneity was then further assessed by between-study variance ( 2 ), obtained from a mixed-effects model with fixed covariate effects and random study effects. Publication bias was assessed graphically using an inverse SE funnel plot and graphed by disease type. Pooled estimates, meta-regression, and other statistical analyses were performed using commercially available software (SAS 9.2; SAS Institute Inc, Cary, NC). Plots were obtained using MIX version 1.7. 15
Results
Studies and Subjects
The search was performed in December 2008 and yielded 1030 articles ( Figure 1 ). Of the original 1030 articles reviewed, 271 were duplicates. A total of 679 articles were excluded for the following reasons: (1) the study did not include patients with a clearly defined rheumatic disease, (2) the study did not include CIMT measurements, or (3) the study did not include a control group. The remaining 80 articles were retrieved for detailed analysis. Six articles did not contain a comparable healthy control group, 11 contained studies based on previously published data, and 5 had missing data. Of the latter group, only 2 sets of authors responded to our request for information; therefore, the 3 other articles (with missing data) were excluded. Sixty studies were available for assessment, comprising 68 comparisons and 6854 subjects (3761 cases and 3093 controls). 16 -75 Translation was required for 8 articles: 1 German, 31 3 Italian, 30,35,52 2 Polish, 25,44 1 Spanish, 69 and 1 Russian. 61 Five articles were submitted to review for arbitration by 1 of us (E.D.S.).
The median age of the study subjects was 45 years (range, 11 to 79 years), with most subjects being female (median, 89%; range, 39% to 100%). Most comparisons (80%) clearly indicated matching of cases and controls by sex and age by design; the remainder showed no significant difference between study groups. Of 68 comparisons, 11 received a minimum of 5 of 9 possible stars (median, 7; range, 5 to 9) of the Newcastle-Ottawa quality assessment scale. Thirty-two comparisons had a score of 8 of higher. The 68 comparisons were divided as follows: 25 (37%) RA, 24 (35%) SLE, 6 (9%) SSc, and 13 (19%) other rheumatic diseases (including 1 ankylosing spondylitis, 1 Behçet disease, 1 connective tissue disorder, 2 familial Mediterranean fever, 1 giant cell arteritis, 4 primary antiphospholipid syndrome, 1 psoriatic arthritis, 1 Sjogren syndrome, and 1 Wegener granulomatosis). Only 3 comparisons included children (2 pediatric SLE and 1 juvenile idiopathic arthritis). 18, 61, 67 Forty-one comparisons (60%) did not specify exclusion of subjects with preexisting CVD, and 27 comparisons (40%) excluded subjects with preexisting CVD (Table 1 ).
CIMT Measurements
Of the 68 comparisons, 52 (76%) measured CIMT using B-mode ultrasonography and 4 (6%) measured CIMT using M-mode ultrasonography; the remaining comparisons did not specify the mode. Fourteen comparisons (21%) clearly specified that they avoided areas of thickening as the result of atheromatous plaques in the CIMT measurement, 19 (28%) indicated that it was possible that their measurements included areas of plaque, and 35 (51%) did not specify. The location of the measurements (ie, segments: CCA, bifurcation carotid artery, or internal carotid artery; far or near wall; or right or left side), measurements used for the summary CIMT value, and reproducibility (number of observers, blinding, and interrater-intrarater reliability) are also included in Table 1 .
In 40 (59%) of the 68 comparisons, the study authors reported a statistically significant greater mean CIMT in patients compared with healthy controls, including 17 (41%) of the 41 comparisons with CVD included and 23 (85%) of the 27 comparisons with CVD excluded. When considering the presence of plaques, 29 (66%) of the 44 comparisons that reported the prevalence of plaques found a significant difference between patients and controls. No agreement between the 2 methods (CIMT measure versus plaque prevalence) was found (ϭϪ0.045).
A summary estimate of the absolute mean difference in CIMT between case and control groups was calculated using a fixed-effects model (overall mean difference, 0.042 mm; 95% CI, 0.037 to 0.048 mm) and a random-effects model (overall summary estimate, 0.061 mm; 95% CI, 0.045 to 0.076).
To estimate the strength and significance of the relationship of the difference in CIMT, the effect size for all comparisons (Cohen's D) was calculated and graphically represented in a forest plot by disease type, ordered by author with meta-analysis weight included ( Figure 2 ). The estimated summary effect size calculated by a fixed-effect model was 0.36 (95% CI, 0.31 to 0.41). The overall estimated summary effect size calculated by a random-effect model was 0.47 (95% CI, 0.34 to 0.60) ( 
Assessment of Heterogeneity and Confounding
To assess publication bias, a funnel plot was produced, with comparisons sorted by the inverse SE of the calculated effect size. A slightly positively skewed distribution with larger samples showing smaller effect sizes was observed similarly for all disease types ( Figure 3 ). To further assess this bias, we used the trim-and-fill procedure, which resulted in an adjusted fixed-effects summary estimate for all comparisons that remained statistically significant and clinically relevant, with an effect size of 0.13 (95% CI, 0.08 to 0.17). The degree of inconsistency in the comparison results was tested using the Q statistic and measured using I 2 . A significant Q statistic of 225 (PϽ0.001) and a high level of variation with an I 2 of 84% (95%CI, 81% to 87%) were found for the overall fixed model (all comparisons). After finding such a high degree of heterogeneity, we progressed to a random-effects model to further define this heterogeneity. Inconsistency in the comparison results was estimated by 2 from the random-effects model. A significant level of heterogeneity was found for the crude model ( 2 ϭ0.22; 95% CI, 0.15 to 0.35) and was used as the reference level for further modeling (Table 2 ). To explore possible sources of heterogeneity, we first investigated age, sex ratio, disease duration, and NOS score independently as possible contributors to between-study variance. None of these 4 variables was found to remain significant in the model. However, disease duration was found to reduce heterogeneity by 22% compared with the crude model. Age, sex ratio, and NOS score barely reduced heterogeneity (range, 1% to 3%). We then considered the methodological factors that could be contributing to heterogeneity. Considering the coronary segment where the IMT was measured, a sensitivity analysis of the 41 comparisons that measured the CIMT in the CCA segment exclusively (ie, excluding the 27 comparisons that did not clearly indicate the measured segment or that included multiple measured segments) resulted in a small increase in the summary estimate of effect size (2%) and no change in residual heterogeneity (data not shown). Considering the ultrasonographic imaging mode used, a sensitivity analysis of the 52 comparisons that specifically used B-mode ultrasonography (excluding the 4 comparisons that used M-mode ultrasonography and the 12 comparisons that did not clearly indicate the method used) resulted in a small increase in summary effect size (6%) but a 14% reduction in residual heterogeneity (data not shown). Considering that the 23 comparisons that clearly indicated areas of plaque were excluded from the CIMT measurement relative to the 45 comparisons that did not, the summary effect size was no different in the model (0.43 versus 0.55; Pϭ0.39) and there was little change in residual heterogeneity (Table 2 ). Finally, considering the 27 comparisons with preexisting CVD excluded relative to the 41 comparisons not excluded, the summary effect size was increased by 91% (0.65 versus 0.34; Pϭ0.01), with an 11% reduction in residual heterogeneity ( Table 2) . When stratifying preexisting CVD excluded by disease type, the 27 comparisons were as follows: 16 of 25 were RA, 4 of 24 were SLE, 2 of 6 were SSc, and 5 of 13 were other rheumatic disease. The ratios between disease types differed significantly (Pϭ0.009). When considering both factors (preexisting CVD excluded and disease type) in the model together, preexisting CVD excluded remained significant (Pϭ0.03) and disease type did not (Pϭ0.89). Residual heterogeneity was reduced by 16% (data not shown).
We then considered a multivariable model that included preexisting CVD excluded as the factor of interest and adjusted for age, sex ratio, and disease duration ( Table 2) . The difference between summary estimates with preexisting CVD excluded versus not remained significant (0.64 versus 0.27; Pϭ0.004); residual heterogeneity was reduced by 43%. To obtain an absolute mean difference representative of the studies included in our analysis, we performed a fixed-effect meta-analysis of the mean difference of comparisons, with preexisting CVD excluded, and obtained a summary estimate of 0.06 mm (95% CI, 0.05 to 0.06 mm). This absolute difference suggests that the effect of rheumatic disease on CIMT with preexisting CVD excluded can be estimated to be a 7-to 8-year increase in age when assuming a linear relationship between age and CIMT thickening (where with every 10-year increase, a thickening of 0.079 mm can be expected). 76 When the analysis was performed with only comparisons that excluded pre-existing CVD, the resulting summary estimates were markedly increased. When considering pediatric populations who, because of the young age of the subjects, are inherently excluding preexisting CVD, the effect sizes were large and similar for both studied diseases: two pediatric SLE studies, 0.73 (95% CI, 0.17 to 1.30) 18 and 0.66 (95% CI, 0.03 to 1.30) 67 and one study of juvenile idiopathic arthritis, 0.74 (95% CI, 0.19 to 1.30). 61 
Discussion
In this article, we reviewed data from 68 comparisons of populations with rheumatic disease populations versus controls, including 6864 subjects who had CIMT measurements reported. Although CIMT is a known strong predictor of cardiovascular events in the general population, 10 and has been predominantly reported in the literature on patients with rheumatic diseases, it has been suggested that detection of carotid plaques by ultrasonography is a more reliable predictor of cardiovascular events. 77 We observed in 59% of the 68 reviewed comparisons that the study authors reported a statistically significant greater mean CIMT in patients with rheumatic diseases compared with healthy controls and a similarly increased prevalence of plaques in 66% of the 44 reviewed comparisons that reported the presence of carotid plaque. Interestingly, no agreement between the 2 methods was observed; however, this likely reflects the considerable differences in methodological approach to inclusion or exclusion of plaques in the CIMT measurement between different study authors. Furthermore, because each rheumatic disease may differ in the amount and type of inflammation, active inflammatory plaques could be fewer but potentially larger and/or more destructive. In this case, patients would potentially have an increased CIMT but fewer plaques.
Significant heterogeneity existed between comparisons; therefore, a random-effects analysis was chosen to best model and explore sources of this heterogeneity. The best metaregression analysis model of the effect size between the CIMT of patients with rheumatic diseases compared with healthy controls adjusted for age, sex ratio, and disease duration. Patients with preexisting CVD were excluded. The resulting significant summary effect size estimate of 0.64 (95% CI, 0.46 to 0.82) represented an overall mean difference of 0.055 mm (95% CI, 0.048 to 0.063 mm). The effect of rheumatic disease on CIMT when excluding preexisting CVD can be estimated to be a 7-to 8-year increase in age.
When considering the effect of including subjects with preexisting CVD, 59% of reviewed comparisons reported a greater mean CIMT in patients with rheumatic diseases; this occurred in 85% of comparisons with CVD excluded and in only 41% of comparisons with CVD included. This was similarly reflected in our random-effects model, with an increase in effect size and a decrease in heterogeneity for the comparisons with CVD excluded. This would suggest that the inclusion of subjects with preexisting CVD might significantly confound the interpretation of the independent effect of rheumatic diseases on CIMT. Although there are too few pediatric comparisons for any conclusive results, this would be consistent with the generally larger effect sizes seen in the 3 pediatric comparisons included, with the lowest possible risk for premature atherosclerosis being the result of Framingham risk factors. 5 The 3 most frequently included rheumatic diseases (ie, RA, SLE, and SSc) had different overall effect sizes. However, these were not as significantly different as the betweencomparison variability, which was high. Also, the number of comparisons per group differed substantially. However, the multiple rheumatic diseases included did contribute to heterogeneity overall. This may be due to the effect of chronic inflammation not being uniform across the rheumatic diseases and subgroups included and the potential for overlap in the diagnostic criteria of some of the rheumatic diseases included. Also, there are many possible reasons to expect differences 4 between disease types because each disease has a different amount and/or type of chronic inflammation, which has been shown to be an important factor leading to premature atherosclerosis. Although all 3 diseases may involve blood vessel inflammation, the type and degree of inflammation differ among the disease. Given that SSc, unlike RA or SLE, always involves some degree of vascular involvement, it may not be surprising that it had 1 of the largest effect sizes. Finally, although the estimate for SLE was the smallest, this may have been confounded again by the fact that too few comparisons excluded subjects with preexisting CVD compared with the other diseases.
Other possible sources of variability include carotid ultrasonographic methods. Comparisons differed by carotid segment investigated; whether both sides or a single side was measured; whether the far wall, the near wall, or both walls were measured; whether the final result was expressed as a mean or a maximal IMT; and which ultrasonographic imaging mode was used (B versus M mode). Reproducibility also has improved steadily since the initial development of the techniques, but it is infrequently reported (34% of comparisons in this review). We only considered comparisons that included healthy age-and sex-matched controls, and most measured the CCA segment and calculated the mean CIMT with a minimum of 3 measures. However, although it is beyond the scope of this review to assess differences between ultrasonographic measurement techniques, it is of interest that most of these technical considerations made little difference and only B-versus M-mode ultrasonography contributed to the observed heterogeneity of the model. We support the suggestion by others 10, 78, 79 of the need to use a standardized protocol for future studies to ensure clinically meaningful results.
Measuring the CIMT in areas of thickening as the result of atheromatous plaques is of definite concern. Although our analysis showed little difference in the summary effect size between healthy and rheumatic disease populations when plaque was included or excluded in the measure, the absolute CIMT measures were somewhat inflated when areas of plaques were potentially included. In future studies, this again stresses the need for a standardized protocol and approach to distinguishing early atherosclerotic plaque formation from thickening of IMT.
This systematic review and meta-analysis clearly demonstrated that there was a significant increase in CIMT in rheumatic disease populations compared with age-and sexmatched healthy controls. However, some limitations are apparent. First, the choice of "healthy controls" as the comparator group comes with challenges that need to be considered. Most healthy controls were volunteers and were generally not described with the same rigor as the cases. This can be problematic when the study design has as its purpose to elicit differences between these groups. Population controls have also served as the comparator group, especially for studying the effects of plaque, and should be considered as a viable alternative. Second, some publication bias was present. This bias is often accentuated when the disease of interest is relatively rare (often the case in rheumatic diseases) because studies in these situations often have a small sample size, with increased variability leading to insignificant comparisons that ultimately remain unpublished. 80, 81 With the large potential sources of heterogeneity that existed between comparisons, sampling bias could become a factor if the reason for the heterogeneity (rheumatic disease population, exclusion of preexisting CVD, or disease duration) could influence the authors' decision on how to report (ie, mean or maximal IMT) the results. We are not overly concerned with this potential problem because most comparisons reported a mean CIMT or both. Finally, although most studies were assessed to be of acceptable quality, it was the comparability of the methodological considerations (ie, independent blind assessment) that mostly affected the NOS score. As previously suggested, a standardized method would lead to less variation and, therefore, better summary effect size estimates.
In conclusion, CIMT was significantly increased in rheumatic disease populations compared with age-and sexmatched healthy populations in our systematic review and meta-analysis of 68 comparisons. The type of rheumatic disease, preexisting atherogenic risk factors, and disease duration were important in considering the utility of CIMT as a surrogate for premature atherosclerosis. Because cardiovascular events are rare in children, CIMT measurements may be particularly useful in younger populations as an end point for epidemiological and treatment studies.
